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Background: To eradicate hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) using a stepwise
infection control strategy that includes an avoidance of antimicrobial prophylaxis (AMP) based on surgical wound
classification and an improvement in operative procedures in gasless single-port urologic surgery.
Methods: The study was conducted at an 801-bed university hospital. Since 2001, in the urology ward, we have
introduced the stepwise infection control strategy. In 2007, surveillance cultures for MRSA in all urological patients
were commenced. The annual incidence of MRSA was calculated as a total number of newly identified MRSA cases
per 1,000 patient days. Trend analysis was performed using a Poisson regression.
Results: Over the study period, 139,866 patients, including 10,201 urology patients, were admitted to our hospital.
Of these patients, 3,719 patients, including 134 ones in the urology ward, were diagnosed with MRSA throughout
the entire hospital. Although the incidence of MRSA increased throughout the entire hospital (p = 0.002), it
decreased significantly in the urology ward (p < 0.0001). Of the 134 cases, 45 (33.6%) were classified as “imported,”
and 89 (66.4%) as “acquired.” In the urology ward, the incidence of acquired MRSA decreased significantly over time
(p < 0.0001), whereas the incidence of imported MRSA did not change over time (p = 0.66). A significant decrease
(p < 0.0001) in the incidence of clinically significant MRSA infection over time was found.
Conclusions: Stepwise infection control strategy that includes a reduction or avoidance of antimicrobial
prophylaxis in minimally invasive surgery can contribute to a reduction in hospital-acquired MRSA.
Trial registration: Current study has approved by the institutional ethical review board (No.1141).
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Minimally invasive surgeryBackground
Methicillin-resistant Staphylococcus aureus (MRSA) re-
sults in longer hospitalization, increased expenses, and
poorer patient prognosis [1]. MRSA has been swiftly in-
creasing worldwide over the past several decades [2].
The indiscriminate use of antibiotics has been identified
as an important factor in the increasing dissemination
of MRSA [3]. A relationship between the consump-
tion of antibiotics and antimicrobial resistance has
been widely documented, leading to the implementation* Correspondence: hi-masu.uro@tmd.ac.jp
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reproduction in any medium, provided the orof antimicrobial control policies [4,5]. Although most hos-
pitals have programs to control the use of antibiotics,
MRSA has continued to increase in the majority of hospi-
tals [6].
Antimicrobial prophylaxis (AMP) for surgery has been
empirically performed to prevent surgical site infection
(SSI) but inadequate use of AMP has been pointed out
as the cause of the dissemination of MRSA. [3,7] Now-
adays, it is widely accepted that a reduction in AMP
should be promoted unless it increases the risk of infec-
tious complications in patients. Recently, it was reported
that the introduction of minimally invasive surgery can
reduce or avoid AMP without increasing the risk of SSIal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ually reduced or avoided in gasless single-port urologic
surgery [9,10] without increasing the risk of SSI [11-14].
However, it has not yet been determined whether an in-
fection control strategy that includes a reduction or
avoidance of AMP in minimally invasive surgery actually
reduces the incidence of MRSA.
Japan is known to have the world’s highest prevalence
of MRSA among the various strains of S. aureus [15].
The incidence of MRSA in our hospital was also rela-
tively high throughout all of the wards in 2000. In order
to eradicate MRSA in our urology ward, since 2001 we
have implemented a stepwise infection control strategy,
including the introduction and development of gasless
single-port surgery concomitant with a reduction or
avoidance of AMP based on surgical wound classifica-
tion. Herein, we present our 10-year study, which has
successfully reduced the nosocomial transmission of
MRSA in our urology ward.
Methods
Setting
The study was conducted at Tokyo Medical and Dental
University (TMDU) Hospital, which is an 801-bed
tertiary-care university hospital with 19 wards, located in
central Tokyo, Japan.
In accordance with the Centers for Disease Control
and Prevention (CDC) guidelines [16], we have intro-
duced a stepwise infection control strategy into daily
clinical practice since 2001. After receiving approval by
the institutional review board, we analyzed impact of theFigure 1 Over view of the stepwise infection control strategy in the ustrategy on the incidence of MRSA retrospectively. All
consecutive patients admitted between January 2000 and
December 2010 constituted the study population.
After investigating the prevalence of MRSA in 2000,
we introduced a stepwise infection control strategy in
the urology ward since 2001 (Figure 1), in addition to
the following hospital-wide standard precautions for in-
fection control measures. The hospital-wide measures
include hand hygiene compliance, strict application of
barrier precautions for patients with MRSA, shortened
hospital stays, and the continuous education of health-
care workers on appropriate hygiene procedures. Pa-
tients who were MRSA-colonized on the basis of clinical
cultures were placed in contact isolation, and decolo-
nization was not attempted unless necessary.
Definitions
On admission, we evaluated whether patients were at
risk for carrying MRSA. These included patients who
were transferred from other hospitals, intensive care
units, or nursing homes and patients who were previ-
ously colonized with MRSA. An MRSA case was defined
as a patient from whom MRSA was recovered from any
site, including a patient infected or colonized with
MRSA. Each MRSA case was counted only once. MRSA
was classified as imported when it was identified within
72 hours of admission or if the patient was previously
known to be an MRSA carrier; otherwise, it was classi-
fied as acquired in our hospital [17-19]. Clinically signifi-
cant MRSA infection (CSMI) was defined as an MRSA
infection associated with clinical symptoms and signs ofrology ward.
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monstration of MRSA [20].
Stepwise infection control strategy
Avoidance and reduction of AMP
The need for AMP generally depends on the surgical
wound classification according to the CDC guidelines
[16]. Based on the CDC guidelines and several urology
guidelines [21,22], we have gradually reduced AMP in
urological surgeries for patients without infectious risk.
In the pre-intervention period, patients routinely re-
ceived intravenous second-generation cephalosporin for
3 to 5 days, followed by oral antibiotics for several days.
Since April 2001, we have reduced the AMP step by step
based on the surgical wound classification [16]. In clean
and clean-contaminated surgeries, patients received
second-generation cephalosporin administered postoper-
atively for 2 to 3 days and immediately before the start
of the operation. In clean urological surgeries, patients
without infectious risk received AMP as follows: between
August 2003 and August 2004: ampicillin sodium/sulbac-
tam sodium immediately before the surgery; between
September 2004 and September 2005: levofloxacin (LVFX)
orally once immediately before the surgery; after October
2005: no AMP was administered [11]. After we confirmed
that perioperative infection had not increased, we ex-
tended the range of application of reducing AMP. In
clean-contaminated urological surgeries, patients received
AMP as follows: between January 2005 and September
2005: tazobactam sodium/piperacillin sodium (TAZ/PIPC)
intravenously immediately before the surgery and for 3
days afterwards; between October 2005 and September
2006: TAZ/PIPC once immediately before the surgery;
after October 2006: LVFX orally once immediately before
the surgery [12,13]. In the transurethral resection of blad-
der tumors, patients received AMP as follows: between
April and September 2006: LVFX orally once immediately
before the surgery; after October 2006: no AMP was ad-
ministered [23]. In contaminated urological surgeries
using bowel segments, patients received cefmetazole on
the operative day only, although prolonged operation and
other morbidity risk factors may support the use of a
prolonged regimen, which should be within three days
according to the European Association of Urology guide-
line [21]. If a perioperative infection was found, antibiotics
were administered immediately according to the drug sen-
sitivity profile of cultured pathogens.
Other than that, in the treatment of urinary tract in-
fection, we use broad-spectrum antimicrobial agents as
initial empiric therapy with the intent of covering mul-
tiple possible pathogens until microbiological results
become available. Once the etiologic pathogen and an-
timicrobial susceptibility data are available, we use an
antibiotic with the narrowest possible spectrum.Improvement of operative procedures and perioperative
management
We have developed and performed gasless single-port
endoscopic surgery as a novel minimally invasive uro-
logic surgery, which has been covered by the Japanese
universal health insurance system since 2008 [9,10].
Through the single port that narrowly permits extraction
of the specimen, a wide working space is made by separ-
ating the anatomical plane extraperitoneally. This space
is maintained with special retractors instead of gas insuf-
flation. The single port is protected by the retractor and
the operative field concomitant with the subcutaneous
space is rinsed with sterile saline. Since April 2008, skin
has been closed by subcuticular suture without ad-
ditional dressing. After introducing the suture, daily bed-
side treatment including change of the dressing, which is
associated with the nosocomial transmission of MRSA,
has been no longer required.
Surveillance cultures
Until March 2007, selective screening, mainly urine cul-
ture, for MRSA was performed in patients at risk for
carrying MRSA at hospital admission and at the time of
bedside treatment. In April 2007, we initiated preopera-
tive surveillance cultures of surgical sites, mainly urine
cultures, in all patients undergoing surgery to evaluate
their infectious risk.
Microbiological procedures
All of the isolates of MRSA were collected from clinical
samples at the clinical microbiology laboratory in our
hospital. S. aureus was confirmed by Clinical and
Laboratory Standards Institute (CLSI) methods [24].
Statistical analysis
The annual incidence of MRSA is calculated as a total
number of newly identified MRSA cases per 1,000 pa-
tient days that is the sum of inpatient days of all patients
during a year.
Given that MRSA cases are rare compared with the
number of admissions, we used Poisson regression
model to obtain temporal trends in the incidence of
MRSA between 2000 and 2010 [25]. In the model the
number of MRSA cases per year was the dependent vari-
able, the actual year of diagnosis was the independent
variable, and the logarithm of patient days was an offset
[26,27].
The model was log (Number of MRSA cases) = log
(Patient days) + B0 + B1 × Year. B0 is the overall inter-
cept and B1 is the coefficient for Year.
If the estimation of the coefficient for Year is signi-
ficantly positive, that indicates the incidence of MRSA
significantly increases with time. All statistical analyses
Tatokoro et al. BMC Urology 2013, 13:35 Page 4 of 7
http://www.biomedcentral.com/1471-2490/13/35were carried out using JMP version 9 (SAS Institute Inc.,
Cary, NC, USA).
Results
Over the study period, 139,866 patients, including
10,201 urology patients, were admitted to TMDU Hos-
pital. For both the entire hospital and the urology ward,
the mean duration of hospital stay decreased by approxi-
mately 40% (Figure 2A), the annual number of hospital
admissions doubled (Figure 2B) and the annual number
of surgeries increased by approximately 50% (Figure 2C)
over time. In fact, number of patient days remained
unchanged.Figure 2 The annual mean duration of hospital stay, number of admi
duration of hospital stay. (B) Annual number of admissions. (C) Annual num
the mean duration of hospital stay decreased by approximately 40% (A), th
number of surgeries increased by approximately 50% (C) over time.Of these patients, 3,719, including 134 urology pa-
tients, were infected or colonized with MRSA. Although
the incidence of MRSA increased throughout the entire
hospital (coefficient for Year, 0.016; 95% CI, 0.0062 to
0.027; p = 0.002), it decreased significantly in the urology
ward (coefficient for Year, -0.12; 95% CI, -0.18 to −0.068;
p < 0.0001) (Figure 3A). Of the 134 cases, 45 (33.6%)
were classified as imported, and 89 (66.4%) as acquired
in our hospital (Table 1). In the urology ward, the inci-
dence of acquired MRSA decreased significantly over
time (coefficient for Year, -0.18; 95% CI, -0.25 to −0.11;
p < 0.0001), whereas imported MRSA did not change
over time (coefficient for Year, -0.020; 95% CI, -0.11 tossions and number of surgeries, 2000-2010. (A) Annual mean
ber of surgeries. For both the entire hospital and the urology ward,
e annual number of hospital admissions doubled (B) and the annual
Figure 3 The annual incidence of methicillin-resistant
Staphylococcus aureus per 1,000 patient days and the
submission rate of bacteriological cultures in the urology ward,
2000-2010. (A) Annual incidence of MRSA colonization or infection
per 1,000 patient days. (B) Annual incidence of MRSA colonization or
infection per 1,000 patient days in the urology ward. (C) Annual
incidence of clinically significant MRSA infection per 1,000 patient
days in the urology ward. (D) Annual submission rate of bacteriological
culture in the urology ward. Although the incidence of MRSA
increased throughout the entire hospital, it decreased significantly in
the urology ward (A). In the urology ward, the incidence of acquired
MRSA decreased significantly, whereas the incidence of imported
MRSA did not change over time (B). A significant decrease in the
incidence of clinically significant MRSA infection over time was found
(C). After introducing surveillance cultures in 2007, the submission rate
of bacteriological cultures increased in 2008 (D).
Table 1 Characteristics of 134 MRSA patients in the
urology ward
Category N=134 (%)
Gender Male 112 84
Female 22 16
Mean age (years, range) 70 (18–94)
Up to 74 90 67
75+ 44 33













Clinically significant MRSA infection 69 51





Imported MRSA 45 34
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54 (61%) had surgical procedures and 66 (74%) received
antibiotics before diagnosis of MRSA (Table 1).Of the 134 MRSA cases in the urology ward, 69 (51%)
developed a CSMI. The major type of CSMI were sur-
gical site (33%), genitourinary tract (22%) (Table 1). No
patient died of CSMI. The incidence of CSMI decreased
after the stepwise implementation of the strategies (coeffi-
cient for Year, -0.17; 95% CI, -0.25 to −0.087; p < 0.0001)
(Figure 3C).
The incidence of MRSA in the urology ward increased
transiently in 2007 when preoperative surveillance cul-
tures of surgical sites was initiated, and decreased again
thereafter. Figure 3D shows the submission rate of bac-
teriological cultures in the urology ward, which was cal-
culated as a total number of submitted bacteriological
cultures divided by total number of admissions during a
year. Before initiating surveillance cultures, those were
obtained in 20% of admitted patients in 2006 that were
at risk for carrying MRSA. After introducing surveillance
cultures, the submission rate of bacteriological cultures
increased to 61% in 2008.
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Our study demonstrates that a large-scale, long-term
stepwise infection control strategy that includes the re-
duction or avoidance of antimicrobial prophylaxis in
minimally invasive surgery contributed to a reduction in
hospital-acquired MRSA and clinically significant MRSA
infections in a urology ward, although the incidence of
MRSA throughout the entire hospital increased despite
the shared antimicrobial control policies [6]. Performing
appropriate antibiotic stewardship, ensuring proper hand
hygiene, cohorting the care of infected or colonized pa-
tients, decreasing unnecessary patient contact, and de-
creasing the length of stay for hospitalized patients are
well-known strategies to prevent the nosocomial trans-
mission of MRSA [28]. Despite the fact that continuous
education of the hospital staff in regard to the trans-
mission of resistant bacteria and the introduction of
hospital-wide wall posters reminding individuals to keep
their hands clean have been instituted throughout our
hospital, the implementation of these measures has not
resulted in a reduction in the incidence of MRSA. In
addition to the aforementioned measures, in the urology
ward, we introduced the reduction of AMP in gasless
single-port surgery as a novel minimally invasive uro-
logic surgery in 2001. Especially in clean urological sur-
geries, AMP has been avoided since 2005 without an
increase in the number of SSIs [11]. After implementa-
tion of our strategy, the incidence of acquired MRSA de-
creased gradually despite the increase throughout the
entire hospital. These findings indicate that a reduction
or avoidance of AMP in minimally invasive urologic sur-
gery could contribute to the management of MRSA in
the urology ward. We believe that the minimally invasive
surgery itself also was associated with the favorable out-
comes. Technically, the rinsing of the operative field and
subcutaneous space with sterile saline and subcuticular
suture without additional dressing may also contribute
to the reduction of SSIs, whose causative agent is often
MRSA [29]. To the best of our knowledge, this is the
first study in regard to the association between the inci-
dence of MRSA and minimally invasive surgery.
In the urology ward, the incidence of MRSA increased
transiently in 2007 and was followed by a decrease
thereafter. We interpreted this phenomenon to be a re-
sult of the introduction of preoperative surveillance cul-
tures of surgical sites in all patients undergoing surgery.
This measure may lead to the detection of MRSA that
had gone unrecognized during the preceding period.
This is also supported by the increased proportion of pa-
tients with MRSA that were detected through surveil-
lance cultures. Active surveillance to screen all patients
for MRSA is more labor intensive and costly than pas-
sive surveillance in the routine course of patient care.
McGinigle et al. reported that the detection of MRSAincreased by 30 to 135% with active surveillance cultures
and that what actually increased was the detection of pa-
tients colonized with MRSA [30].
The mechanism regarding the association between the
controlled use of antibiotics and the incidence of MRSA
has been discussed. The prolonged administration of
antibiotic therapy or inadequate dosing of antibiotics
may select for methicillin-resistant isolates in an overall
population of S. aureus [31]. Several studies have sug-
gested a positive association between antimicrobial con-
sumption and the incidence of MRSA colonization or
infection within the hospital setting [3,28]. Length of
hospital stay has been demonstrated to be a predisposing
factors in the acquisition of MRSA [32]. It is of note
that, despite the fact that throughout the entire hospital
the mean duration of hospital stay decreased by approxi-
mately 40%, the incidence of MRSA increased. The rea-
son for this discrepancy remains unknown.
This study has limitations and the results must be
interpreted with care. First, the study was conducted in
a single center in Japan. Second, this study was not a
case control study and it is possible that unmeasured con-
founders, such as the staff compliance to the hospital-
wide standard precautions, the number of contaminated
surgeries, underlying comorbidities as infectious risk and
antibiotic consumption, were associated with the inci-
dence of MRSA. Therefore, we could not clarify the im-
pact of the reduction or avoidance of AMP and minimally
invasive surgery on the incidence of MRSA because of the
observational design.Conclusions
Our study demonstrates that a large-scale, long-term
stepwise infection control strategy that includes the re-
duction or avoidance of antimicrobial prophylaxis in
minimally invasive surgery over 10 years could contrib-
ute to the reduction in hospital-acquired MRSA and
clinically significant infections in a urology ward of a
university hospital.Abbreviations
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